Cancer Cells Steal Mitochondria from Immune Cells to Spread to Lymph Nodes
Tumor cells hijack mitochondria from immune cells, crippling anti-tumor defenses and fueling lymph node metastasis via cGAS/STING signaling.
Summary
Researchers at Stanford discovered that tumor cells actively steal mitochondria from immune cells including NK cells and CD8 T cells. This theft weakens immune defenses by reducing antigen presentation and cytotoxic capacity. The hijacked mitochondria then fuse with the cancer cell's own mitochondrial network, leaking mitochondrial DNA into the cytosol and activating the cGAS/STING pathway. This triggers type I interferon signaling, helping cancer cells evade immune detection and colonize lymph nodes. Blocking mitochondrial transfer machinery — including cGAS, STING, or type I interferon — significantly reduced lymph node metastasis in experimental models, revealing a novel therapeutic target in cancer spread.
Detailed Summary
Cancer metastasis to lymph nodes is a critical step in disease progression, yet how tumor cells overcome immune defenses in these immune-rich environments has remained poorly understood. This study from Stanford University, published in Cell Metabolism, identifies a striking mechanism: tumor cells systematically steal mitochondria from surrounding immune cells to disable anti-tumor immunity and power their own spread.
The researchers found that tumor cells hijack mitochondria from a broad range of immune cells, including natural killer (NK) cells and CD8 T cells. When immune cells lose their mitochondria, they suffer reduced antigen-presentation capacity, diminished co-stimulatory signaling, and impaired cytotoxic function — effectively disarming the body's frontline cancer defenses at the moment they are most needed.
Once inside cancer cells, the stolen mitochondria fuse with existing mitochondrial networks and begin leaking mitochondrial DNA (mtDNA) into the cytosol. This activates the cGAS/STING innate immune pathway, which paradoxically benefits the tumor by triggering type I interferon-mediated immune evasion programs — co-opting the very immune machinery designed to fight pathogens.
Critically, blocking components of this mitochondrial transfer process — including cGAS, STING, or type I interferon signaling — significantly reduced cancer metastasis to lymph nodes in experimental models. This positions mitochondrial hijacking as both a mechanistic explanation for lymph node colonization and a potential therapeutic target.
Caveats include that findings are based on experimental models, and translation to human clinical outcomes requires further validation. The breadth of immune cell types affected and cancer types studied also needs expansion. Nonetheless, this work reframes mitochondria not just as metabolic organelles but as immunological weapons in the tumor microenvironment.
Key Findings
- Tumor cells hijack mitochondria from NK cells, CD8 T cells, and other immune cells, broadly impairing anti-tumor immunity.
- Mitochondria theft reduces immune cell antigen presentation, co-stimulation, activation, and cytotoxic capacity.
- Stolen mitochondria fuse with cancer cell networks and leak mtDNA, activating cGAS/STING and type I interferon signaling.
- Blocking cGAS, STING, or type I interferon significantly reduced lymph node metastasis in experimental models.
- Mitochondrial hijacking is identified as a common tumor strategy to both weaken immunity and fuel lymph node colonization.
Methodology
The study used experimental cancer models to observe mitochondrial transfer between immune and tumor cells. Genetic and pharmacological blockade of cGAS, STING, and type I interferon pathways were employed to assess effects on lymph node metastasis. Mechanistic analyses included mitochondrial fusion assays, mtDNA cytosolic leak detection, and immune cell functional assays.
Study Limitations
The study relies primarily on experimental models, so direct applicability to human cancer biology requires clinical validation. The range of cancer types and immune cell populations examined may not capture the full complexity of human tumor microenvironments. Conflict of interest disclosures note advisory and patent relationships related to mitochondrial transfer technology among some authors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.